Holen Sie sich die Stockscreener-App
1.96
2.00%
-0.04
Handel nachbörslich:
1.96
Schlusskurs vom Vortag:
$2.00
Offen:
$2
24-Stunden-Volumen:
500.94K
Relative Volume:
0.53
Marktkapitalisierung:
$70.39M
Einnahmen:
$832.00K
Nettoeinkommen (Verlust:
$-135.12M
KGV:
-0.3218
EPS:
-6.09
Netto-Cashflow:
$-124.69M
1W Leistung:
-6.22%
1M Leistung:
-14.04%
6M Leistung:
-77.18%
1J Leistung:
-62.95%
1-Tages-Spanne:
$1.905
$2.04
1-Wochen-Bereich:
$1.90
$2.06
52-Wochen-Spanne:
$1.74
$14.75
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Firmenname
Inovio Pharmaceuticals Inc
Sektor
Branche
Telefon
(858) 410-3134
Adresse
6769 MESA RIDGE RD., SAN DIEGO, PA
Vergleichen Sie INO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.96 | 70.39M | 832.00K | -135.12M | -124.69M | -6.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-14 | Eingeleitet | Stephens | Overweight |
| 2024-01-25 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-11-09 | Herabstufung | Maxim Group | Buy → Hold |
| 2022-11-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-19 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2022-05-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-12-29 | Fortgesetzt | Jefferies | Hold |
| 2021-09-10 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-24 | Eingeleitet | Jefferies | Hold |
| 2021-03-23 | Eingeleitet | BofA Securities | Neutral |
| 2021-02-12 | Eingeleitet | Oppenheimer | Outperform |
| 2020-11-17 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2020-11-10 | Hochstufung | ROTH Capital | Sell → Neutral |
| 2020-09-28 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2020-09-28 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-07-01 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2020-06-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-06-26 | Herabstufung | Stifel | Buy → Hold |
| 2020-05-21 | Eingeleitet | The Benchmark Company | Buy |
| 2020-04-30 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2020-03-13 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-03-13 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-12-19 | Eingeleitet | ROTH Capital | Buy |
| 2018-02-15 | Bestätigt | Maxim Group | Buy |
| 2017-10-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-06 | Eingeleitet | Citigroup | Buy |
| 2017-06-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2017-05-24 | Bestätigt | Maxim Group | Buy |
| 2017-03-16 | Hochstufung | Maxim Group | Hold → Buy |
| 2017-03-16 | Herabstufung | Piper Jaffray | Overweight → Neutral |
Alle ansehen
Inovio Pharmaceuticals Inc Aktie (INO) Neueste Nachrichten
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $12.40 Average Price Target from Brokerages - MarketBeat
Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Price Target at $12.40 - Defense World
DNA Nanotechnology Market Overall Study Report 2025-2032 | - openPR
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
BlackRock, Inc. Expands Stake in Inovio Pharmaceuticals Inc. - GuruFocus.com
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Anal Cancer Market Forecast 2034: Clinical Trials, Medication, - openPR
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
INOVIO Reports Inducement Grant Under Inducement Plan - GuruFocus.com
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
INOVIO to Present at Oppenheimer Healthcare Life Sciences Conference - MyChesCo
Vanguard Group Inc. Reduces Stake in Inovio Pharmaceuticals Inc. - GuruFocus.com
INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - StreetInsider.com
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
INOVIO's Next Big Move: CEO Reveals Future of DNA Medicine at Major Healthcare Conference - StockTitan
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Head to Head Review: Inovio Pharmaceuticals (NASDAQ:INO) and Hypertension Diagnostics (OTCMKTS:HDII) - Defense World
INOVIO Reports Promising Long-Term Data for INO-3107 in Treating RRP - MSN
Inovio Pharma Stock Slips Ahead of Q3 Earnings: Retail’s Bullish - MSN
Barclays PLC Buys 25,116 Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Defense World
INOVIO Targets 2025 as Transformational Year with Major Progress on INO-3107 - MSN
What is HC Wainwright’s Estimate for INO FY2024 Earnings? - Defense World
Inovio (INO) Soars 19.0%: Is Further Upside Left in the Stock? - MSN
Inovio Pharmaceuticals (NASDAQ:INO) Given New $3.00 Price Target at HC Wainwright - Defense World
Anal Cancer Market on Track for Major Expansion by 2034, - openPR
Inovio Pharmaceuticals (NASDAQ:INO) Price Target Cut to $3.00 by Analysts at HC Wainwright - MarketBeat
JMP Securities Reaffirms “Market Outperform” Rating for Inovio Pharmaceuticals (NASDAQ:INO) - Defense World
Inovio Pharmaceuticals' SWOT analysis: dna-based immunotherapy firm faces hurdles - Investing.com Australia
Inovio Pharmaceuticals' SWOT analysis: dna-based immunotherapy firm faces hurdles By Investing.com - Investing.com South Africa
Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Price Target at $11.50 - MarketBeat
Inovio Pharmaceuticals' (INO) "Market Outperform" Rating Reiterated at JMP Securities - MarketBeat
INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accom - GuruFocus.com
INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments - Longview News-Journal
What's Going On With Inovio Pharmaceuticals (INO) Stock? - Benzinga
Why Inovio Pharmaceuticals (INO) Stock Is Skyrocketing - Benzinga
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Shares Purchased by State Street Corp - Defense World
Inovio Pharmaceuticals Q3 Earnings Tops Estimates, Lifts Retail Sentiment - MSN
Inovio Completes Enrollment In The Phase 1 U.S. Trial Of Ino-4800 For Covid-19 Dna Vaccine Interim Results Expected In June - Reuters
Finanzdaten der Inovio Pharmaceuticals Inc-Aktie (INO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):